Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

PHASE2RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Type 1 DiabetesHeart Failure
Interventions
DRUG

Sotagliflozin

Sodium-glucose Co-transporter inhibitor

DRUG

Placebo

Matched placebo

Trial Locations (15)

AB25 2ZN

RECRUITING

Aberdeen Royal Infirmary, Aberdeen

CB2 0QQ

RECRUITING

Addenbrookes Hospital, Cambridge

DD1 9SY

RECRUITING

Ninewells Hospital, Dundee

EH16 4SA

RECRUITING

Royal Infirmary of Edinburgh, Edinburgh

G31 2ER

RECRUITING

Glasgow Royal Infirmary, Glasgow Clinical Research Facility, Glasgow

LE5 4PW

RECRUITING

Leicester General Hospital, Leicester

L9 7AL

RECRUITING

Aintree University Hospital, Liverpool

SA14 8QF

RECRUITING

Prince Philip Hospital, Llanelli

SE1 9RT

RECRUITING

Guy's Hospital, London

SW17 0QT

RECRUITING

St George's University Hospitals NHS Foundation Trust, London

M13 9WL

RECRUITING

Manchester Royal Infirmary Hospital, Manchester

M23 9LT

RECRUITING

Wythenshawe Hospital, Manchester

M8 5RB

RECRUITING

North Manchester General Hospital, Manchester

S5 7AU

RECRUITING

Northern General Hospital, Sheffield

SO30 3JB

RECRUITING

Moorgreen Hospital, Southampton

All Listed Sponsors
collaborator

Lexicon Pharmaceuticals

INDUSTRY

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

University of Dundee

OTHER